Today: 10 November 2025
Subscribe
Browse Category

NYSE:LLY News 17 October 2025 - 6 November 2025

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC (12:51 p.m. ET), NVO traded around $47.30, down ~2.4% on the day (intraday range: $46.91–$49.49; volume ~29.3M). The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire What’s moving NVO today White House deal cuts
6 November 2025
 ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader access President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce U.S. costs and expand coverage for in‑demand weight‑loss medicines. The plan includes Medicare coverage for obesity treatment, expected to carry $50 monthly copays for eligible beneficiaries,
6 November 2025
 ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) stockanalysis.com marketbeat.com. That’s up ~9–10% from early October nasdaq.com. Trading volumes have been heavy, and LLY remains near its 52-week high (~$935) marketbeat.com. MarketBeat notes LLY’s 50-day moving average is ~$780 marketbeat.com, reflecting the recent surge. Institutional ownership is high (~82.5% by funds marketbeat.com) and sentiment is bullish. Blowout Q3 & Raised Guidance Lilly’s Q3 (announced Oct 30) blew past forecasts. Revenue was $17.60 billion (+54% YoY) with EPS $7.02 marketbeat.com, versus consensus ~$16.1 B/$5.9. Key GLP-1 drugs led the surge. The company
2 November 2025
 ·  ·  ·  ·  · 
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

October Stock Moves and Market Reaction Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year (roughly in line with the health-care index). The stock then saw a mid-month wobble.
30 October 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

LLY Stock Snapshot and Recent Moves Eli Lilly’s stock (NYSE: LLY) has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53 investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly (closing about 2% lower in the past week). Trading volume and technical indicators suggest a consolidation phase after the recent rally intellectia.ai intellectia.ai. Over the past 12 months LLY has significantly outperformed the broader market, in large part thanks to its GLP-1 diabetes/obesity franchise. Wall Street now assigns it a
30 October 2025
 ·  ·  ·  ·  · 
Stock Market Today 11.10.2025

2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

Best Stock Market Performance as of October 29, 2025 Global Markets Rally to New Highs Stock markets around the world are on fire heading into the final days of October 2025. Hong Kong’s Hang Seng Index – up about 34–35% so far this year – is the planet’s best-performing major index advisorperspectives.com. After a brutal multi-year slump, Hong Kong’s market came roaring back thanks to ultra-cheap valuations and China’s post-pandemic stimulus. Investors flooded into undervalued Chinese tech and consumer stocks, driving a dramatic rebound. As a result, the Hang Seng has erased its losses from prior years and is flirting
29 October 2025
 ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Stock Performance and Recent Moves Eli Lilly (NYSE: LLY) has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1 ts2.tech ts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rally ts2.tech. By Oct. 23, LLY was trading
23 October 2025
 ·  ·  ·  ·  · 
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Market News & Today’s Financial Outlook Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market trading reuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor names reuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset
22 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

Markets & AI: Rally Amid Record Highs U.S. markets enter the week in a buoyant mood, shrugging off recent headwinds. Major indices closed Oct. 17 near all-time peaks (Dow ~46,200, S&P 500 ~6,664) ts2.tech, buoyed by blockbuster earnings and the promise of Fed rate cuts. Technology and AI-related stocks are powering the gains: the Nasdaq, in particular, has jumped about +15% so far this year ts2.tech. Investors point to robust corporate results (58% of S&P companies beat Q3 forecasts ts2.tech) and cooling inflation/interest-rate pressures. Big tech remains center stage. NVIDIA’s incredible momentum illustrates the theme: its GPUs are the backbone of
20 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Key Facts – October 18, 2025 Nasdaq Ends Week Higher Amid Roller-Coaster Trading After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points (+0.52%) on the day reuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high (~23,000) set earlier this month, and is up roughly 15–17% for the year to date ts2.tech – a strong performance reflecting 2025’s bullish
18 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

LLY Stock Skyrockets, Then Dips on Pricing Jitters Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1 ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospects ts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchises
17 October 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop